APL_40470/2024

TREATMENT OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA PATIENTS BY AN INHIBITOR OF COMPLEMENT

BerufungenHauptberufungCourt of AppealAppeal RoP220.1—

Übersicht Entscheidungen Zitate Dokumente Zeitverlauf

Parteien

Kläger

Alexion Pharmaceuticals, Inc.(AstraZeneca Group)

Vertreter: Wolrad Prinz zu Waldeck Und Pyrmont (Freshfields Bruckhaus Deringer); Christopher Stothers (Freshfields Bruckhaus Deringer); Elena Hennecke (Freshfields Bruckhaus Deringer); Gregor König (Szynka Tilmann von Renesse); Claudia Hertzsch (Szynka Tilmann von Renesse)

Beklagte

Samsung Bioepis NL B.V.

Vertreter: Andrea Ritter (Simmons & Simmons); Peter Meyer (Simmons & Simmons); Scott Parker (Simmons & Simmons); Elsa Glauert (Simmons & Simmons); Fritz Lahrtz (Simmons & Simmons)

Richter

Klaus GrabinskiPresident of the Court of Appeal
Peter BlokLegally qualified judge and judge-rapporteur
Emmanuel GougéLegally qualified judge
Eric EnderlinTechnically qualified judge
Anna HedbergTechnically qualified judge

Patente

EP3167888

CPC-Codes: A61P31/04, A61P25/18, A61P29/02, A61K39/395, A61K2039/505, A61P7/02, A61P25/26, A61P13/02, A61P15/10, A61P17/00, A61P7/00, A61P25/28…

Sektor: Organic Chemistry

Ausgang

PI abgelehnt

Eingereicht: —

Erste Entscheidung: 20. Dez. 2024

Sprache: —

The Court of Appeal dismissed Alexion's appeal against the Hamburg Local Division's refusal to grant provisional measures against Samsung Bioepis regarding patent EP 3167888. The Court addressed the interpretation of patent claims containing linguistic errors and the relevance of prosecution history.